Research programme: protease inhibitors - SuperGen
Latest Information Update: 20 Apr 2011
At a glance
- Originator SuperGen
- Mechanism of Action Peptide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 20 Apr 2011 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 03 Aug 2007 Preclinical trials in Cardiovascular disorders in USA (unspecified route)